| Zacks Company Profile for Alkermes plc (ALKS : NSDQ) |
|
|
| |
| • Company Description |
| Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major therapeutic areas. Alkermes holds a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders including schizophrenia, depression, addiction and multiple sclerosis. Alkermes derives revenues on net sales of its proprietary products: Vivitrol & Aristada, and manufacturing and/or royalty revenues on net sales of products commercialized by the company's partners. These include Risperdal Consta, Invega Sustenna/Xeplion, Invega Trinza/Trevicta, Ampyra/Fampyra and Bydureon. Interesting late-stage candidate in the company's pipeline include nemvaleukin alfa developed for treating advanced solid tumors. Its proprietary drugs are Vivitrol & Aristada.
Number of Employees: 1,800 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $30.13 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,865,141 shares |
| Shares Outstanding: 164.90 (millions) |
| Market Capitalization: $4,968.48 (millions) |
| Beta: 0.51 |
| 52 Week High: $36.45 |
| 52 Week Low: $22.90 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
11.59% |
5.75% |
| 12 Week |
-16.05% |
-9.30% |
| Year To Date |
4.76% |
8.87% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Richard F. Pops - Chairman and Chief Executive Officer
Blair C. Jackson - Executive Vice President; Chief Operating Officer
Samuel J. Parisi - Vice President; Finance
Emily Peterson Alva - Director
Shane M. Cooke - Director
|
|
Peer Information
Alkermes plc (CORR.)
Alkermes plc (RSPI)
Alkermes plc (CGXP)
Alkermes plc (BGEN)
Alkermes plc (GTBP)
Alkermes plc (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G01767105
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/23/25
|
|
Share - Related Items
Shares Outstanding: 164.90
Most Recent Split Date: 5.00 (2.00:1)
Beta: 0.51
Market Capitalization: $4,968.48 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.30 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $1.29 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 7.00 |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: 12.28% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 07/23/25 |
|
|
|
| |
